Management of anticoagulation in patients with acute gastrointestinal bleeding

Digestive and Liver Disease

Volumn 47, Issue 8, 2015, Pages 621-627

  Radaelli, Franco ^a   Dentali, Francesco ^b   Repici, Alessandro ^c   Amato, Arnaldo ^a   Paggi, Silvia ^a   Rondonotti, Emanuele ^a   Dumonceau, Jean Marc ^d  

^a VALDUCE HOSPITAL   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d Diagnostic and Therapeutic Gastroenterology and Endoscopy   (Argentina)

Author keywords

Anticoagulation reversal; Gastrointestinal bleeding; Oral anticoagulants

Indexed keywords

ACTIVATED CARBON; ANTICOAGULANT AGENT; ANTIVITAMIN K; HEMOSTATIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN; ACENOCOUMAROL; COAGULATING AGENT; DABIGATRAN; RIVAROXABAN; VITAMIN K GROUP;

ALGORITHM; ANTICOAGULATION; BLOOD CLOTTING DISORDER; CLINICAL DECISION MAKING; DISEASE SEVERITY; ENDOSCOPY; GASTROENTEROLOGIST; GASTROINTESTINAL HEMORRHAGE; HEMODIALYSIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STOMACH LAVAGE; THROMBOSIS; TREATMENT INDICATION; ACUTE DISEASE; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; GASTROINTESTINAL ENDOSCOPY;

ACENOCOUMAROL; ACUTE DISEASE; ALGORITHMS; ANTICOAGULANTS; COAGULANTS; DABIGATRAN; ENDOSCOPY, GASTROINTESTINAL; GASTROINTESTINAL HEMORRHAGE; HUMANS; RIVAROXABAN; VITAMIN K; WARFARIN;

EID: 84946153534     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2015.03.029     Document Type: Review

References (83)

1. Wysowski D.K., Nourjah P., Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Archives of Internal Medicine 2007, 167:1414-1419.
2. Gomes T. Rates of hemorrhage during Warfarin therapy for atrial fibrillation. Canadian Medical Association Journal 2013, 185:E121-E127.
3. http://www.agenziafarmaco.gov.it/sites/default/files/Rapporto_OsMED_2013.pdf.
4. Lip G.Y., Agnelli G. Edoxaban: a focused review of its clinical pharmacology. European Heart Journal 2014, 35:1844-1855.
5. Cullen M.W., Kim S., Piccini J.P., et al. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circulation: Cardiovascular Quality and Outcomes 2013, 6:461-469.
6. Le Heuzey J.Y., Ammentorp B., Darius H., et al. Data from the PREFER IN AF registry. Thrombosis and Haemostasis 2014, 111:833-841.
7. Desai N.R., Krumme A.A., Schneeweiss S., et al. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation - quality and cost implications. American Journal of Medicine 2014, 127:1075-1082.
8. Zekowitz M.D., Bridgers S.L., James K.E., et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. New England Journal of Medicine 1992, 327:1406-1412.
9. Connolly S.J., Laupacis A., Gent M., et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. Journal of the American College of Cardiology 1991, 18:349-355.
10. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. New England Journal of Medicine 1990, 323:1505-1511.
11. Stroke Prevention in Atrial Fibrillation investigators Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991, 84:527-539.
12. Di Marco J.P., Flaker G., Waldo A.L., et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. American Heart Journal 2005, 149:650-656.
13. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine 2011, 365:981-992.
14. Mercaldi C.J., Ciarametaro M., Hahn B., et al. Cost efficiency of anticoagulation with warfarin to prevent stroke in Medicare beneficiaries with nonvalvular atrial fibrillation. Stroke 2011, 42:112-118.
15. Hylek E.M., Evans-Molina C., Shea C., et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007, 115:2689-2696.
16. Fihn S.D., Callahan C.M., Martin D.C., et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Annals of Internal Medicine 1996, 124:970-979.
17. Hippisley-Cox J., Coupland C. Predicting risk of upper gastrointestinal bleed and intracranial bleed with anticoagulants: cohort study to derive a validate QBleed scores. British Medical Journal 2014, 349:g4606.
18. Coleman C.I., Sobieraj D.M., Winkler S., et al. Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation. International Journal of Clinical Practice 2012, 66:53-63.
19. Marmo R., Koch M., Cipolletta L., et al. Predicting mortality in non-variceal upper gastrointestinal bleeders: validation of the Italian PNED Score and Prospective Comparison with the Rockall Score. American Journal of Gastroenterology 2010, 105:1284-1291.
20. Abu Daya H., Eloubeidi M., Tamim H., et al. Opposing effects of aspirin and anticoagulants on morbidity and mortality in patients with upper gastrointestinal bleeding. Journal of Digestive Diseases 2014, 15:283-292.
21. Hreinsson J.P., Kalaitzakis E., Gudmundsson S., et al. Upper gastrointestinal bleeding: incidence, etiology and outcomes in a population-based setting. Scandinavian Journal of Gastroenterology 2013, 48:439-447.
22. Aoki T., Nagata N., Niikura R., et al. Recurrence and mortality among patients hospitalized for acute lower gastrointestinal bleeding. Clinical Gastroenterology and Hepatology 2014, [Epub ahead of print].
23. Thomopoulos K.C., Mimidis K.P., Theocharis G.J., et al. Acute upper gastrointestinal bleeding in patients on long term oral anticoagulation therapy: endoscopic findings, clinical management and outcome. World Journal of Gastroenterology 2005, 11:1365-1368.
24. Halbritter K., Beyer-Westendorf J., Nowotny J., et al. Hospitalization for vitamin-K-antagonist-related bleeding: treatment patterns and outcome. Journal of Thrombosis and Haemostasis 2013, 11:651-659.
25. Irwin J., Fergunson R., Weilert F., et al. Supratherapeutic anticoagulation at presentation is associated with reduced mortality in nonvariceal upper gastrointestinal hemorrhage. Endoscopy International Open 2014, 2:E148-E152.
26. Marmo R., Koch M., Cipolletta L., et al. Predicting mortality in patients with in-hospital nonvariceal upper GI bleeding: a prospective, multicenter database study. Gastrointestinal Endoscopy 2014, 79:741-749.
27. Ashburner J.M., Go A.S., Reynolds K., et al. Comparison of frequency and outcome of major gastrointestinal hemorrhage in patients with atrial fibrillation on versus not receiving warfarin therapy (from the ATRIA and ATRIA-CVRN cohorts). American Journal of Cardiology 2015, 115:40-46.
28. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine 2009, 361:1139-1151.
29. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine 2011, 365:883-891.
30. Holster I.L., Valkhoff V.E., Kuipers E.J., et al. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology 2013, 145. 105-12.e15.
31. Chai-Adisaksopha C., Crowther M., Isayama T., et al. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 2014, 124:2450-2458.
32. Hernandez I., Baik S.H., Piñera A., et al. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Internal Medicine 2015, 175:18-24.
33. Manatsathit W., Al-Hamid H., Leelasinjaroen P., et al. Management of gastrointestinal bleeding in patients anticoagulated with dabigatran compared with warfarin: a retrospective, comparative case review. Cardiovascular Diagnosis and Therapy 2014, 4:224-231.
34. Radaelli F., Paggi S., Terruzzi V., et al. Management of warfarin-associated coagulopathy in patients with acute gastrointestinal bleeding: a cross-sectional physician survey of current practice. Digestive and Liver Disease 2011, 43:444-447.
35. Veitch A.M., Baglin T.P., Gershlick A.H., et al. Guidelines for the management of anticoagulant and antiplatelet therapy in patients undergoing endoscopic procedures. Gut 2008, 57:1322-1329.
36. ASGE Standards of Practice Committee, Anderson M.A., Ben-Menachem T., et al. Management of antithrombotic agents for endoscopic procedures. Gastrointestinal Endoscopy 2009, 70:1060-1070.
37. Dworzynski K., Pollit V., Kelsey A., et al. Management of acute upper gastrointestinal bleeding: summary of NICE guidance. British Medical Journal 2012, 344:e3412.
38. Barkun A.N., Bardou M., Kuipers E.J., et al. International Consensus Upper Gastrointestinal Bleeding Conference Group. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Annals of Internal Medicine 2010, 152:101-113.
39. Ansell J., Hirsh J., Hylek E., et al. Pharmacology and management of the vitamin K antagonists. American College of Chest Physician. Evidence-based clinical practice guidelines. Chest 2008, 133:160S-198S.
40. Tran H.A., Chunilal S.D., Harper P.L., et al. An update of consensus guidelines for warfarin reversal. Medical Journal of Australia 2013, 198:198-199.
41. Keeling D., Baglin T., Tait C., et al. Guidelines on oral anticoagulation with warfarin - fourth edition. British Journal of Haematology 2011, 154:311-324.
42. Jairath V., Kahan B.C., Logan R.F.A., et al. National audit of the use of surgery and radiological embolization after failed endoscopic haemostasis for non-variceal upper gastrointestinal bleeding. British Journal of Surgery 2012, 99:1672-1680.
43. Choudari C.P., Rajgopal C., Palmer K.R. Acute gastrointestinal haemorrhage in anticoagulated patients: diagnoses and response to endoscopic treatment. Gut 1994, 35:464-466.
44. Lubetsky A., Yonath H., Olchovsky D., et al. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Archives of Internal Medicine 2003, 163:2469-2473.
45. Lubetsky A., Shasha Y., Olchovsky D., et al. Impact of pre-treatment INR level on the effect of intravenous low dose vitamin K in patients with excessive anticoagulation. Thrombosis and Haemostasis 2003, 90:71-76.
46. Patriquin C., Crowther M. Treatment of warfarin-associated coagulopathy with vitamin K. Expert Review of Hematology 2011, 4:657-665.
47. Holland L.L., Nrooks J.P. Toward rational fresh frozen plasma transfusion: the effect of plasma transfusion on coagulation test results. American Journal of Clinical Pathology 2006, 126:133-139.
48. Franchini M., Lippi G. Prothrombin complex concentrates: an update. Blood Transfusion 2010, 8:149-154.
49. Leissinger C.A., Blatt P.M., Hoots W.K., et al. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. American Journal of Hematology 2008, 83:137-143.
50. Sarode R., Milling T.J., Refaai M.A., et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 2013, 128:1234-1243.
51. Tazarourte K., Riou B., Tremey B., et al. Guideline-concordant administration of prothrombin complex concentrate and vitamin K is associated with decreased mortality in patients with severe bleeding under vitamin K antagonist treatment (EPAHK study). Critical Care 2014, 18:R81.
52. Karaca M.A., Erbil B., Ozmen M.M. Use and effectiveness of prothrombin complex concentrates vs fresh frozen plasma in gastrointestinal hemorrhage due to warfarin usage in the ED. American Journal of Emergency Medicine 2014, 32:660-664.
53. Voils S.A., Baird B. Systematic review: 3-factor versus 4-factor prothrombin complex concentrate for warfarin reversal: does it matter. Thrombosis Research 2012, 130:833-840.
54. Dentali F., Imberti D., Tamburini Pemunian E., et al. Risk factors for suboptimal efficacy of 3-factor prothrombin complex concentrates in emergency VKA anticoagulation reversal. Thrombosis and Haemostasis 2014, 112:621-623.
55. Holbrook A., Schulman S., Witt D., et al. Evidence based management of anticoagulant therapy. Chest 2012, 141(2 Suppl.):e152S-184S.
56. Hickey M., Gatien M., Taljaard M., et al. Outcomes of urgent warfarin reversal with frozen plasma versus prothrombin complex concentrate in the emergency department. Circulation 2013, 128:360-364.
57. Dentali F., Marchesi C., Pierfranceschi M.G., et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists: a meta-analysis. Thrombosis and Haemostasis 2011, 106:429-438.
58. Levi M., Peters M., Buller H.R., et al. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Critical Care Medicine 2005, 33:883-890.
59. O'Connell K.A., Wood J.J., Wise R.P., et al. Thromboembolic adverse events after the use of recombinant factor VIIa. Journal of the American Medical Association 2006, 295:293-298.
60. Awad N.I., Cocchio C. Activated prothrombin complex concentrates for the reversal of anticoagulant-associated coagulopathy. Pharmacy and Therapeutics 2013, 38:696-701.
61. Dentali F., Crowther M.A. Management of excessive anticoagulant effect due to vitamin K antagonists. Hematology 2008, 26:6-70.
62. Desai J., Granger C.B., Weitz J.I., et al. Novel oral anticoagulants in gastroenterology practice. Gastrointestinal Endoscopy 2013, 78:227-239.
63. Baron T.H., Kamath P.S., McBane R.D. New anticoagulant and antiplatelet agents: a primer for the gastroenterologist. Clinical Gastroenterology and Hepatology 2014, 12:187-195.
64. Cuker A., Siegal D., Crowther M.A., et al. Laboratory measurements of anticoagulant activity of the non-vitamin K oral anticoagulants. Journal of the American College of Cardiology 2014, 64:1128-1139.
65. Desai J., Kolb J.M., Weitz J.I., et al. Gastrointestinal bleeding with the new oral anticoagulants - defining the issues and the management strategies. Thrombosis and Haemostasis 2013, 110:205-212.
66. Makris M., Tait C.R., Mumford A.D., et al. Guideline on the management of bleeding in patients on antithrombotic agents. British Journal of Haematology 2012, 160:35-46.
67. Abraham N.S., Castillo D.L. Novel anticoagulants: bleeding risk and management strategies. Current Opinion in Gastroenterology 2013, 29:676-683.
68. Heidbuchel H., Verhamme P., Alings M., et al. European heart and rhythm association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013, 15:625-651.
69. Van Ryn J., Stangier J., Haertter S., et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thrombosis and Haemostasis 2010, 103:1116-1127.
70. Siegal D.M., Cuker A. Reversal of novel oral anticoagulants in patients with major bleeding. Journal of Thrombosis and Thrombolysis 2013, 35:391-398.
71. Levy J.H., Levi M. New oral anticoagulant-induced bleeding: clinical presentation and management. Clinics in Laboratory Medicine 2014, 34:575-586.
72. Kaatz S., Crowther M. Reversal of target-specific oral anticoagulants. Journal of Thrombosis and Thrombolysis 2013, 36:195-202.
73. Gomez-Outes A., Suarez-Gea M.L., Lecumberri R., et al. Specific antidotes in development for reversal of novel anticoagulants: a review. Recent Patents on Cardiovascular Drug Discovery 2014, 9:2-10.
74. Ansell J.E., Bakhru S.H., Laulicht B.E., et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. New England Journal of Medicine 2014, 371:2141-2142.
75. Fawole A., Daw H.A., Crowther M.A. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban. Cleveland Clinic Journal of Medicine 2013, 80:443-451.
76. Stangier J., Rathgen K., Stahle H., et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatranetexilate: an open-label, parallel-group, single-centre study. Clinical Pharmacokinetics 2010, 49:259-268.
77. Baumann Kreuziger L.M., Reding M.T. Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices. Thrombosis Research 2013, 132:e161-e163.
78. Witt D.M., Delate T., Garcia D.A., et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Archives of Internal Medicine 2012, 172:1484-1491.
79. Sengupta N., Feuerstein J.D., Patwardhan V.R., et al. The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized in patients with gastrointestinal bleeding: a prospective study. American Journal of Gastroenterology 2014, [Epub ahead of print].
80. Qureshi W., Mittal C., Patsias I., et al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. American Journal of Cardiology 2014, 113:662-668.
81. Bonow R.O., Carabello B.A., Chatterjee K., et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Journal of the American College of Cardiology 2008, 52:e1-e142.
82. Nishimura R.A., Otto C.M., Bonow R.O., et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of Thoracic and Cardiovascular Surgery 2014, 148:e1-e132.
83. Roudaut R., Serri K., Lafitte S. Thrombosis of prosthetic heart valves: diagnosis and therapeutic considerations. Heart 2007, 93:137-142.